These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 30325997)
1. Reassessment of 4-Cycle Etoposide and Cisplatin as the Standard of Care for Good-Risk Metastatic Germ Cell Tumors. Fein DE; Paulus JK; Mathew P JAMA Oncol; 2018 Dec; 4(12):1661-1662. PubMed ID: 30325997 [No Abstract] [Full Text] [Related]
2. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy. Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157 [TBL] [Abstract][Full Text] [Related]
3. Studies of the Australasian Germ Cell Trial Group: the management of advanced testis cancer. Raghavan D; Levi J; Thomson D; Harvey V Prog Clin Biol Res; 1990; 350():319-29. PubMed ID: 1696742 [No Abstract] [Full Text] [Related]
4. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy. Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521 [TBL] [Abstract][Full Text] [Related]
5. [Chemotherapy of disseminated germ cell tumors of the testis]. Tiuliandin SA Sov Med; 1987; (11):78-81. PubMed ID: 2451298 [No Abstract] [Full Text] [Related]
6. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M; J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040 [TBL] [Abstract][Full Text] [Related]
15. Multiple relapses of mature teratoma, germinal and non-germ cell cancer in a patient treated with chemotherapy for testicular non-seminomatous germ cell cancer. McKendrick JJ; Mead GM; Cowlishaw D Clin Oncol (R Coll Radiol); 2003 May; 15(3):128-31. PubMed ID: 12801050 [No Abstract] [Full Text] [Related]
16. Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin. Brada M; Horwich A; Peckham MJ Cancer Treat Rep; 1987 Jun; 71(6):655-6. PubMed ID: 2438041 [TBL] [Abstract][Full Text] [Related]
17. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. Wozniak AJ; Samson MK; Shah NT; Crawford ED; Ford CD; Altman SJ; Stephens RL; Natale RB; Bouroncle BA; Blumenstein BA J Clin Oncol; 1991 Jan; 9(1):70-6. PubMed ID: 1702148 [TBL] [Abstract][Full Text] [Related]
19. Alternatives to standard BEP x 3 in good-prognosis germ cell tumors--you bet your life. Nichols C; Kollmannsberger C J Natl Cancer Inst; 2010 Aug; 102(16):1214-5. PubMed ID: 20631340 [No Abstract] [Full Text] [Related]
20. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors. Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]